EMEA-001220-PIP07-20-M01

Table of contents

Key facts

Invented name
Olumiant
Active substance
Baricitinib
Therapeutic area
Infectious diseases
Decision number
P/0364/2022
PIP number
EMEA-001220-PIP07-20-M01
Pharmaceutical form(s)
  • Age-appropriate oral liquid dosage form
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019
Route(s) of administration
  • Gastric use
  • Oral use
Contact for public enquiries
Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating